Hussman Strategic Advisors Inc. Acquires New Holdings in Emergent Biosolutions Inc (EBS)

Hussman Strategic Advisors Inc. acquired a new stake in shares of Emergent Biosolutions Inc (NYSE:EBS) during the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 25,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,646,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Greenwood Capital Associates LLC increased its holdings in Emergent Biosolutions by 20.4% in the 2nd quarter. Greenwood Capital Associates LLC now owns 5,553 shares of the biopharmaceutical company’s stock worth $280,000 after buying an additional 940 shares during the period. Summit Global Investments increased its holdings in Emergent Biosolutions by 9.4% in the 2nd quarter. Summit Global Investments now owns 12,800 shares of the biopharmaceutical company’s stock worth $646,000 after buying an additional 1,100 shares during the period. Sei Investments Co. increased its holdings in Emergent Biosolutions by 33.0% in the 2nd quarter. Sei Investments Co. now owns 5,106 shares of the biopharmaceutical company’s stock worth $258,000 after buying an additional 1,268 shares during the period. Macquarie Group Ltd. increased its holdings in Emergent Biosolutions by 4.3% in the 2nd quarter. Macquarie Group Ltd. now owns 31,457 shares of the biopharmaceutical company’s stock worth $1,588,000 after buying an additional 1,297 shares during the period. Finally, Envestnet Asset Management Inc. increased its holdings in Emergent Biosolutions by 20.5% in the 2nd quarter. Envestnet Asset Management Inc. now owns 8,796 shares of the biopharmaceutical company’s stock worth $445,000 after buying an additional 1,494 shares during the period. Hedge funds and other institutional investors own 83.12% of the company’s stock.

Emergent Biosolutions stock opened at $63.86 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.15 and a current ratio of 5.59. Emergent Biosolutions Inc has a 12 month low of $36.38 and a 12 month high of $67.24. The company has a market capitalization of $3.02 billion, a price-to-earnings ratio of 33.61, a P/E/G ratio of 1.23 and a beta of 1.23.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported $1.07 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.88 by $0.19. Emergent Biosolutions had a return on equity of 15.09% and a net margin of 16.55%. The business had revenue of $220.20 million for the quarter, compared to analyst estimates of $208.94 million. During the same quarter in the prior year, the firm posted $0.13 EPS. The business’s quarterly revenue was up 118.5% compared to the same quarter last year. Sell-side analysts expect that Emergent Biosolutions Inc will post 2.45 earnings per share for the current year.

In other Emergent Biosolutions news, CEO Daniel Abdun-Nabi sold 90,776 shares of the company’s stock in a transaction that occurred on Wednesday, September 5th. The stock was sold at an average price of $60.18, for a total value of $5,462,899.68. Following the sale, the chief executive officer now owns 257,343 shares in the company, valued at approximately $15,486,901.74. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Chairman Fuad El-Hibri sold 36,318 shares of the company’s stock in a transaction that occurred on Tuesday, August 14th. The stock was sold at an average price of $55.98, for a total value of $2,033,081.64. The disclosure for this sale can be found here. In the last 90 days, insiders sold 187,522 shares of company stock worth $11,293,890. Insiders own 16.50% of the company’s stock.

Several equities analysts recently weighed in on the stock. Cantor Fitzgerald set a $68.00 price target on shares of Emergent Biosolutions and gave the stock a “buy” rating in a report on Tuesday, September 11th. Wells Fargo & Co set a $65.00 price target on shares of Emergent Biosolutions and gave the stock a “hold” rating in a report on Wednesday, August 29th. Argus increased their price target on shares of Emergent Biosolutions to $70.00 and gave the stock an “average” rating in a report on Tuesday, September 11th. They noted that the move was a valuation call. Goldman Sachs Group upgraded shares of Emergent Biosolutions from a “neutral” rating to a “buy” rating and increased their price target for the stock from $60.00 to $75.00 in a report on Friday. Finally, Cowen reiterated a “hold” rating and issued a $49.00 price target on shares of Emergent Biosolutions in a report on Wednesday, August 29th. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Emergent Biosolutions currently has a consensus rating of “Buy” and a consensus target price of $64.13.

Emergent Biosolutions Profile

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

See Also: Earnings Per Share

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply